SURGICAL MITRAL
VALVE SOLUTIONS
TISSUE HEART VALVES (THV)

 

The Abbott portfolio of surgical mitral valves includes stented tissue valves, mechanical valves, and annuloplasty rings that are designed to rebuild healthier hearts.

TISSUE HEART VALVES (THV)

EPIC™ MITRAL STENTED TISSUE VALVE

The Epic™ Platform has been proven over time and defined by strong hemodynamics, intuitive implantability, and a future-facing design that gives you and your patients more choices when it comes to preserving long-term treatment paths.


TREATING TODAY, PRESERVING TOMORROW

This generation of the Epic™ Platform has been built on the Biocor™ legacy of excellent durability, proven performance and unparalleled implantability—and reimagined with the future of transcatheter interventions in mind.

It is the surgical valve platform that gives you and your patients more choices when it comes to preserving long-term treatment paths.

 

FIND OUT MORE ABOUT:

MITRAL REGURGITATION TREATMENT OPTIONS


Mitral

  • Low stent post height is less likely to obstruct the left ventricular outflow tract (LVOT)1
  • Epic™ valve leaflets are not prone to forming a curtain between stent posts when opened; curtaining can result in LVOT obstruction

   *For 27 mm valve size, measured from the farthest point of the cuff.

HEAR WHAT SURGEONS FROM AROUND THE WORLD THINK ABOUT THE EPIC™ VALVE
 

Eric Charbonneau, MD, FRCSC

Vinod Thourani, MD

Taichi Sakaguchi, MD

Sven Lehmann, MD, MBA, HCM

Streamlined customizable implantation
  • Stent symmetry eliminates the need for specific orientation2
  • Flexible polymer stent offers more forgiving insertion and seating
  • Short rinse time of 2 x 10 seconds2
  • Epic™ mitral valve ratcheting holder reduces risk of suture looping and offers a true one-cut release
  • Epic™ platform cuff options allow for secure suture placement while limiting suture drag and parachuting forces
     
Exceptional durability across patient populations

LINX™ ANTICALCIFICATION (AC) TREATMENT MAY IMPROVE LONG-TERM PERFORMANCE AND DURABILITY.*

10 YEARS

95.7 ± 2.6%†

Freedom from SVD, All patient ages (Epic™ Mitral Valve)4

98.6 ± 0.8%†

Freedom from SVD, All patient ages (Epic™ Aortic & Epic™ Mitral Valve)4


SVD: structural valve deterioration.
*There is no clinical data currently available that evaluates the long-term impact of AC tissue treatment in humans.
†From stand-alone aortic or mitral valve replacements.

 

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

Epic™ HCP testimonial

Epic™ Mitral & Supra Aortic stented tissue valves HCP testimonial

Epic™ Mitral Valve

Epic™ Mitral stented tissue valve with Linx™ AC technology

Webinar: Aortic & Mitral Valve Disease

Webinar 2022: Management of aortic and mitral valve disease

EACTS 2022: SMV repair vs replacement

EACTS 2022 Symposium: Surgical Mitral Valve Repair versus Replacement in the Modern Era of Transcatheter Valve Interventions.

References
  1. Guler N, Ozkara C, Akyol A. Left ventricular outflow tract obstruction after bioprosthetic mitral valve replacement with posterior mitral leaflet preservation. Tex Heart Inst J. 2006;33(3):399–401.
    www.ncbi.nlm.nih.gov/pmc/articles/PMC1592274/.
  2. Epic™ Plus Instructions for Use.
  3. Allen KB, Chhatriwalla AK, Cohen DJ, et al. Bioprosthetic valve fracture to facilitate transcatheter valve-in-valve implantation. Ann Thorac Surg. 2017;104(5):1501–1508.
    doi.org/10.1016/j.athoracsur.2017.04.007.
  4. Jawad K, Lehmann S, Koziarz A, et al.  Midterm results after St Jude Medical Epic porcine xenograft for aortic, mitral, and double valve replacement. J Cardiac Surg. 2020;35(8):1769–1777.
    doi.org/10.1111/jocs.14554.
  5.  Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958–1966. doi:10.1093/eurheartj/ehq222.
    doi.org/10.1093/eurheartj/ehq222.
  6. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77(4):450–500.
    www.jacc.org/doi/10.1016/j.jacc.2020.11.035.
  7. Mick SL, Keshavamurthy S, Gillinov AM. Mitral valve repair vs replacement. Ann Cardiothorac Surg. 2015;4(3):230–7.
    doi.org/10.3978/j.issn.2225-319X.2015.03.01..
  8. Tests performed by and data on file at Abbott.
  9. Magna Mitral Ease* Instructions for Use.
  10. Medtronic Mosaic* Bioprosthesis Aortic and Mitral Brochure. #UC200103933b EN.
  11.  Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation. 1997:95(2):479 –488.
    doi.org/10.1161/01.CIR.95.2.479.
  12. Kelly SJ, Ogle MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at Society for Biomaterials, Sixth World Biomaterials Congress Transaction.
    May 2000:1353.
  13. Frater RWM, Seifter E, Liao K, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. 1st ed. Silent Partners, Inc; 1997:105–113.
  14. Vyavahare NR, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577–585.
    doi.org/10.1002/(SICI)1097-4636(19980615)40:4%3C577::AID-JBM9%3E3.0.CO;2-C.

*Indicates a third-party trademark, which is the property of its respective owner.

 

© Abbott 2023. All rights reserved. 9-EH-5-14462-01 08-2023

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.